ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1042

Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 1434

Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
Abstract Number: 1495

Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Abstract Number: 1640

Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions
Abstract Number: 1630

Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Abstract Number: 0208

Musculoskeletal Immune-Related Adverse Effects of Immune Checkpoint Inhibitors at a Single Site in a Hispanic Population in Puerto Rico
Abstract Number: 1193

Musculoskeletal Ultrasound Instruction in US and Canadian Pediatric Rheumatology Fellowship Programs
Abstract Number: 0849

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health
Abstract Number: 0706

Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Abstract Number: 1490

Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity
Abstract Number: 0435

Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071
Abstract Number: 0722

Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Abstract Number: 0541

N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis
Abstract Number: 1564

Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
Abstract Number: 1635

Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].